Chembio Diagnostics' (CEMI) CEO Letter to Stockholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Chembio’s CEO Letter to Stockholders
April 3, 2023 4:15 PM EDTMEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA.
April 3, 2023
Fellow Chembio Stockholders,
As previously communicated, Chembio Diagnostics, Inc. (Chembio or the Company) entered into an Agreement and Plan of Merger (the Merger Agreement), dated as of January 31, 2023, with Biosynex SA (Biosynex), and Project Merci Merger Sub, Inc., a Nevada corporation and wholly-owned indirect subsidiary of Biosynex (the Purchaser). Pursuant to the Merger... More
